Updated Covid vaccines need to target XBB omicron variants this fall, FDA staff says

Updated Covid vaccines need to target XBB omicron variants this fall, FDA staff says


Syringe with Covid-19 vaccine against the XBB Variant. Fight against virus Covid-19 Coronavirus, Vaccination and immunization.

Undefined Undefined | Istock | Getty Images

U.S. Food and Drug Administration staff on Monday said updated Covid boosters should target XBB omicron subvariants for the upcoming fall and winter vaccination campaign. 

The U.S. should use a monovalent vaccine targeting either XBB.1.5, XBB.1.16, or XBB.2.3, collectively the dominant strains nationwide, the staff said in a briefing document. 

The FDA staff made the conclusion ahead of a meeting on Thursday, when a panel of external advisors to the agency will recommend a strain for new Covid shots to target later this year. There is no set date for when the vaccination campaign will begin.

Vaccine manufacturers will be expected to update their shots once that strain is selected.

Pfizer, Moderna and Novavax are already developing versions of their respective vaccines targeting XBB.1.5 and other circulating variants.

The upcoming strain selection will be crucial to those companies’ abilities to compete in the fall, when the U.S. is expected to shift vaccine distribution to the private sector. That means all three companies will start selling their updated Covid shots directly to health-care providers.

The FDA staff’s decision comes weeks after an advisory group to the World Health Organization recommended that Covid booster shots target XBB variants. 

Scientists have said that XBB strains are some of the most immune-evasive subvariants to date.

Those strains accounted for more than 95% of Covid cases in the U.S. as of early June, according to the FDA staff. 

They noted that the proportion of XBB.1.5 cases is declining, but both XBB.1.16 and XBB.2.3 are “on the rise.” 

Last year’s Covid boosters were bivalent, meaning they targeted the original strain of the virus and omicron variants BA.4 and BA.5. Those variants dominated cases nationwide last fall and winter. 

Uptake has been sluggish. Only about 17% of the U.S. population has gotten Pfizer and Moderna’s bivalent boosters since they were approved in September, according to the Centers for Disease Control and Prevention.



Source

Healthy Returns: New study casts doubts on RFK Jr.’s reasons for gutting key vaccine panel
Health

Healthy Returns: New study casts doubts on RFK Jr.’s reasons for gutting key vaccine panel

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks as he attends a press conference with Centers for Medicare and Medicaid Services Administrator Mehmet Oz to discuss health insurance reform, at the Department of Health and Human Services in Washington, D.C., U.S., June 23, 2025. Kevin Mohatt | Reuters A version of […]

Read More
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Health

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors.  The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and […]

Read More
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
Health

Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

A box of Ozempic made by Novo Nordisk, at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price, as drugmakers face mounting political pressure to lower prices in […]

Read More